CCO Treatment Updates

Targeted Therapies in the Treatment of Non-Small-Cell Lung Cancer

Update on Targeted Therapies in Advanced NSCLC

Module 1 of 1

Faculty:
Roy S. Herbst, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/12/07

Expiration Date: 01/11/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Roy S. Herbst, MD, PhD, discusses the most recent advances in targeted therapies for NSCLC and how they will be applied to clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
Describe the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
Recall how EGFR inhibitors and other multi-targeted kinase inhibitors in development for NSCLC may impact clinical practice

Interactive Case Challenges

A 40-Year-Old Female Nonsmoker Diagnosed With Adenocarcinoma Consistent With Primary Non-Small-Cell Lung Cancer

Faculty:
David S. Ettinger, MD

CME CREDIT INFORMATION

Release Date: 01/10/07

Expiration Date: 01/09/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

David S. Ettinger, MD, explores optimal approaches to first-line and second-line therapy in a patient who presents with advanced nonsquamous NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
Discuss the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
Recall second-line therapies used in non-small-cell lung cancer

Management of a 50-Year-Old Male Smoker With Advanced Non-Small-Cell Lung Cancer

Faculty:
Alan B. Sandler, MD

CME CREDIT INFORMATION

Release Date: 02/07/07

Expiration Date: 02/06/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Alan B. Sandler, MD, explores optimal treatment approaches for a male patient with a 40 pack/year smoking history diagnosed with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
Describe the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
Recall optimal dosing and frequency of bevacizumab for the treatment of non-small-cell lung cancer

Management of a 48-Year-Old Smoker With NSCLC

Faculty:
Chandra P. Belani, MD

CME CREDIT INFORMATION

Release Date: 02/13/07

Expiration Date: 02/12/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Chandra P. Belani, MD, explores optimal treatment approaches for a male patient with a 100 pack/year smoking history diagnosed with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiangiogenic agents combined with platinum-based chemotherapies in patients with advanced non-small-cell lung cancer
Describe the safety and efficacy of combining vascular endothelial growth factor and epidermal growth factor receptor inhibitors in the treatment of advanced non-small-cell lung cancer
Recall optimal dosing and frequency of bevacizumab for the treatment of non-small-cell lung cancer

CCO Slideset

Targeted Therapies in the Treatment of Advanced NSCLC

Format: Microsoft PowerPoint (.ppt) | File size: 712 KB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.